A Randomized, Double-blind, Placebo-controlled Pharmacokinetic and Pharmacodynamic Two Part Cohort Study of JNJ-54452840 in Subjects With Reduced Systolic Function Heart Failure and Elevated Levels of Anti-Beta 1 Adrenergic Receptor Autoantibodies

Trial Profile

A Randomized, Double-blind, Placebo-controlled Pharmacokinetic and Pharmacodynamic Two Part Cohort Study of JNJ-54452840 in Subjects With Reduced Systolic Function Heart Failure and Elevated Levels of Anti-Beta 1 Adrenergic Receptor Autoantibodies

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs Mibenratide (Primary)
  • Indications Heart failure
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Janssen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Apr 2014 Planned End Date changed from 1 Nov 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 08 Apr 2014 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top